cabozantinib
FDA Approves Cabometyx for pNET and epNET
The FDA granted approval for cabozantinib for patients 12 years of age and older with previously treated, ...
MARCH 31, 2025
FDA Grants Cabometyx New Indication for HCC
New treatment indicated for most common cause of liver cancer.
JANUARY 18, 2019
Load more